166 related articles for article (PubMed ID: 36808524)
1. A specific anti-cyclin D1 intrabody represses breast cancer cell proliferation by interrupting the cyclin D1-CDK4 interaction.
Zhao J; Wu Y; Xiao T; Cheng C; Zhang T; Gao Z; Hu S; Ren Z; Yu X; Yang F; Li G
Breast Cancer Res Treat; 2023 Apr; 198(3):555-568. PubMed ID: 36808524
[TBL] [Abstract][Full Text] [Related]
2. A Cyclin D1-Specific Single-Chain Variable Fragment Antibody that Inhibits HepG2 Cell Growth and Proliferation.
Wu Y; Tang W; Cao Y; Jiang D; Zhao L; Zhao J; Zhang Y; Li C; Cheng C; Wang S; Yang F; Zhu X; Li G
Biotechnol J; 2020 Aug; 15(8):e1900430. PubMed ID: 32170989
[TBL] [Abstract][Full Text] [Related]
3. Validation of cyclin D1/CDK4 as an anticancer drug target in MCF-7 breast cancer cells: Effect of regulated overexpression of cyclin D1 and siRNA-mediated inhibition of endogenous cyclin D1 and CDK4 expression.
Grillo M; Bott MJ; Khandke N; McGinnis JP; Miranda M; Meyyappan M; Rosfjord EC; Rabindran SK
Breast Cancer Res Treat; 2006 Jan; 95(2):185-94. PubMed ID: 16319987
[TBL] [Abstract][Full Text] [Related]
4. Anticancer activity of britannin through the downregulation of cyclin D1 and CDK4 in human breast cancer cells.
Hamzeloo-Moghadam M; Aghaei M; Abdolmoham Madi MH; Fallahian F
J Cancer Res Ther; 2019; 15(5):1105-1108. PubMed ID: 31603118
[TBL] [Abstract][Full Text] [Related]
5. Bisphenol S promotes the cell cycle progression and cell proliferation through ERα-cyclin D-CDK4/6-pRb pathway in MCF-7 breast cancer cells.
Lin Z; Zhang X; Zhao F; Ru S
Toxicol Appl Pharmacol; 2019 Mar; 366():75-82. PubMed ID: 30684532
[TBL] [Abstract][Full Text] [Related]
6. Growth inhibition of human MDA-mB-231 breast cancer cells by delta-tocotrienol is associated with loss of cyclin D1/CDK4 expression and accompanying changes in the state of phosphorylation of the retinoblastoma tumor suppressor gene product.
Elangovan S; Hsieh TC; Wu JM
Anticancer Res; 2008; 28(5A):2641-7. PubMed ID: 19035289
[TBL] [Abstract][Full Text] [Related]
7. Cyclin D1 is dispensable for G1 control in retinoblastoma gene-deficient cells independently of cdk4 activity.
Lukas J; Bartkova J; Rohde M; Strauss M; Bartek J
Mol Cell Biol; 1995 May; 15(5):2600-11. PubMed ID: 7739541
[TBL] [Abstract][Full Text] [Related]
8. Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
Kim HS; Lee WJ; Lee SW; Chae HW; Kim DH; Oh Y
Horm Metab Res; 2010 Mar; 42(3):165-72. PubMed ID: 19960406
[TBL] [Abstract][Full Text] [Related]
9. Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells.
Carlson BA; Dubay MM; Sausville EA; Brizuela L; Worland PJ
Cancer Res; 1996 Jul; 56(13):2973-8. PubMed ID: 8674031
[TBL] [Abstract][Full Text] [Related]
10. Ribociclib (LEE011) suppresses cell proliferation and induces apoptosis of MDA-MB-231 by inhibiting CDK4/6-cyclin D-Rb-E2F pathway.
Li T; Xiong Y; Wang Q; Chen F; Zeng Y; Yu X; Wang Y; Zhou F; Zhou Y
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):4001-4011. PubMed ID: 31588803
[TBL] [Abstract][Full Text] [Related]
11. BZL101, a phytochemical extract from the Scutellaria barbata plant, disrupts proliferation of human breast and prostate cancer cells through distinct mechanisms dependent on the cancer cell phenotype.
Marconett CN; Morgenstern TJ; San Roman AK; Sundar SN; Singhal AK; Firestone GL
Cancer Biol Ther; 2010 Aug; 10(4):397-405. PubMed ID: 20574166
[TBL] [Abstract][Full Text] [Related]
12. The prognostic significance and value of cyclin D1, CDK4 and p16 in human breast cancer.
Peurala E; Koivunen P; Haapasaari KM; Bloigu R; Jukkola-Vuorinen A
Breast Cancer Res; 2013 Jan; 15(1):R5. PubMed ID: 23336272
[TBL] [Abstract][Full Text] [Related]
13. RAF inhibitor LY3009120 sensitizes RAS or BRAF mutant cancer to CDK4/6 inhibition by abemaciclib via superior inhibition of phospho-RB and suppression of cyclin D1.
Chen SH; Gong X; Zhang Y; Van Horn RD; Yin T; Huber L; Burke TF; Manro J; Iversen PW; Wu W; Bhagwat SV; Beckmann RP; Tiu RV; Buchanan SG; Peng SB
Oncogene; 2018 Feb; 37(6):821-832. PubMed ID: 29059158
[TBL] [Abstract][Full Text] [Related]
14. Involvement of G1/S cyclins in estrogen-independent proliferation of estrogen receptor-positive breast cancer cells.
Bindels EM; Lallemand F; Balkenende A; Verwoerd D; Michalides R
Oncogene; 2002 Nov; 21(53):8158-65. PubMed ID: 12444551
[TBL] [Abstract][Full Text] [Related]
15. Cyclic AMP negatively controls c-myc transcription and G1 cell cycle progression in p210 BCR-ABL transformed cells: inhibitory activity exerted through cyclin D1 and cdk4.
Williamson EA; Burgess GS; Eder P; Litz-Jackson S; Boswell HS
Leukemia; 1997 Jan; 11(1):73-85. PubMed ID: 9001421
[TBL] [Abstract][Full Text] [Related]
16. Ara-c induces cell cycle G1/S arrest by inducing upregulation of the INK4 family gene or directly inhibiting the formation of the cell cycle-dependent complex CDK4/cyclin D1.
Sun F; Li N; Tong X; Zeng J; He S; Gai T; Bai Y; Liu L; Lu K; Shen J; Han M; Lu C; Dai F
Cell Cycle; 2019 Sep; 18(18):2293-2306. PubMed ID: 31322047
[TBL] [Abstract][Full Text] [Related]
17. Anti-tumor potential of 15,16-dihydrotanshinone I against breast adenocarcinoma through inducing G1 arrest and apoptosis.
Tsai SL; Suk FM; Wang CI; Liu DZ; Hou WC; Lin PJ; Hung LF; Liang YC
Biochem Pharmacol; 2007 Dec; 74(11):1575-86. PubMed ID: 17869226
[TBL] [Abstract][Full Text] [Related]
18. Resistance to cyclin-dependent kinase (CDK) 4/6 inhibitors confers cross-resistance to other CDK inhibitors but not to chemotherapeutic agents in breast cancer cells.
Ogata R; Kishino E; Saitoh W; Koike Y; Kurebayashi J
Breast Cancer; 2021 Jan; 28(1):206-215. PubMed ID: 32860163
[TBL] [Abstract][Full Text] [Related]
19. Troglitazone inhibits growth of MCF-7 breast carcinoma cells by targeting G1 cell cycle regulators.
Yin F; Wakino S; Liu Z; Kim S; Hsueh WA; Collins AR; Van Herle AJ; Law RE
Biochem Biophys Res Commun; 2001 Sep; 286(5):916-22. PubMed ID: 11527386
[TBL] [Abstract][Full Text] [Related]
20. Formononetin promotes cell cycle arrest via downregulation of Akt/Cyclin D1/CDK4 in human prostate cancer cells.
Li T; Zhao X; Mo Z; Huang W; Yan H; Ling Z; Ye Y
Cell Physiol Biochem; 2014; 34(4):1351-8. PubMed ID: 25301361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
